Erythroferrone inhibits the induction of hepcidin by BMP6

Blood

Volumn 132, Issue 14, 2018, Pages 1473-1477

  Arezes, Joaõ ^a   Foy, Niall ^b   McHugh, Kirsty ^a   Sawant, Anagha ^b   Quinkert, Doris ^a   Terraube, Virginie ^b   Brinth, Alette ^b   Tam, May ^b,c   LaVallie, Edward R ^b   Taylor, Stephen ^a   Armitage, Andrew E ^a   Pasricha, Sant Rayn ^a,d,e   Cunningham, Orla ^b   Lambert, Matthew ^b   Draper, Simon J ^a   Jasuja, Reema ^b   Drakesmith, Hal ^a,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PFIZER INC   (United States)

^c Pfizer Biotherapeutics RD   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; ERYTHROFERRONE; ERYTHROPOIETIN; HEPCIDIN; MESSENGER RNA; MYELOPID; NEUTRALIZING ANTIBODY; OSTEOGENIC PROTEIN 1; RECOMBINANT PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; UNCLASSIFIED DRUG; CTRP15 PROTEIN, MOUSE; CYTOKINE; IRON; MUSCLE PROTEIN; SMAD PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ERYTHROBLAST; ERYTHROPOIESIS; GENE TARGETING; HEP-G2 CELL LINE; HUH-7 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MRNA EXPRESSION LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TIME RESOLVED FLUORESCENCE SPECTROSCOPY; ANIMAL; CELL LINE; LIVER; METABOLISM;

ANIMALS; BONE MORPHOGENETIC PROTEIN 6; CELL LINE; CYTOKINES; HEP G2 CELLS; HEPCIDINS; HUMANS; IRON; LIVER; MALE; MICE; MUSCLE PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 85054445360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-06-857995     Document Type: Article

References (20)

1. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.
2. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704): 2090-2093.
3. Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanismof action of hepcidin. Blood. 2018; 131(8):899-910.
4. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: Interacting factors in abnormal iron metabolism leading to iron overload in b-thalassemia. Hematol Oncol Clin North Am. 2010;24(6): 1089-1107.
5. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-3735.
6. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006; 55(6):667-674.
7. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010; 95(3):505-508.
8. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
9. Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood. 2017; 130(10):1243-1246.
10. Yadin D, Knaus P, Mueller TD. Structural insights into BMP receptors: Specificity, activation and inhibition. Cytokine Growth Factor Rev. 2016;27:13-34.
11. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.
12. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4): 478-481.
13. Armitage AE, Lim PJ, Frost JN, et al. Induced disruption of the iron-regulatory hormone hepcidin inhibits acute inflammatory hypoferraemia. J Innate Immun. 2016;8(5):517-528.
14. Pasricha SR, Lim PJ, Duarte TL, et al. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nat Commun. 2017; 8(1):403.
15. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic proteinspecific response elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883-4891.
16. Wang CY, Core AB, Canali S, et al. Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice. Blood. 2017; 130(1):73-83.
17. Cuny GD, Yu PB, Laha JK, et al. Structureactivity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008;18(15): 4388-4392.
18. Nai A, Rubio A, Campanella A, et al. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood. 2016; 127(19):2327-2336.
19. Aschemeyer S, Gabayan V, Ganz T, Nemeth E, Kautz L. Erythroferrone and matriptase-2 independently regulate hepcidin expression. Am J Hematol. 2017;92(5):E61-E63.
20. Canali S, Wang CY, Zumbrennen-Bullough KB, Bayer A, Babitt JL. Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6. Am J Hematol. 2017; 92(11):1204-1213.